Résumé
Les lymphomes de la zone marginale (LZM) représentent un groupe de lymphomes individualisé en trois sous-groupes distincts, dépendant de leurs sites d’envahissement: (i) les lymphomes extra-ganglionnaires de la ZM ou lymphomes de MALT (Mucosa Associated Lymphoid Tissue), (ii) les lymphomes spléniques de la zone marginale (avec ou sans lymphocytes villeux), (iii) les lymphomes ganglionnaires (avec ou sans cellules monocytoïdes) (1, 2). Malgré cette classification, la relative rareté de ces lymphomes et les difficultés de les distinguer des autres lymphomes de bas grade est un obstacle à conduire des analyses épidémiologiques précises et d’en décrire l’évolution clinique. Par ailleurs, il n’existe pas d’étude prospective importante publiée, ce qui rend difficile les décisions thérapeutiques, ni de marqueurs cliniques ou biologiques validés qui pourraient aider à prédire une maladie plus agressive. Les données épidémiologiques, cliniques et thérapeutiques les plus récentes vont être décrites ci-après.
Preview
Unable to display preview. Download preview PDF.
Références
Harris NL, Jaffe ES, Stein H, et al. (1994) A revised European-American Classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 84: 1361-92
Jaffe ES, Harris NL, Stein H, Vardiman J (2008) World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press
Thieblemont C, Felman P, Berger F, et al. (2002) Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 3: 41–7
Farinha P, Gascoyne R (2005) Helicobacter pylori and MALT Lymphoma. Gastroenterology 128: 1579–1605
Suarez F, Lortholary O, Hermine O, Lecuit M (2006) Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107: 3034–44
Hermine O, Lefrere F, Bronowicki J, et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 11: 89–94
Thieblemont C, Bastion Y, Berger F, et al. (1997) Mucosaassociated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analsyis of 108 patients. J Clin Oncol 15: 1624–30
Zucca E, Conconi A, Pedrinis E, et al. (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101: 2489–95
Thieblemont C, Berger F, Dumontet C, et al. (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95: 802–806d
Conconi A, Martinelli G, Thieblemont C, et al. (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 15: 2741–5
Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. (2001) Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357: 39–40
Thieblemont C, Felman P, Callet-Bauchu E, et al. (2003) Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 4: 95–103
Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. (2005) Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 106: 1831–8
Thieblemont C, Nasser V, Felman P, et al. (2004) Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103: 2727–37
Paydas S, Yavuz S, Disel U, et al. (2003) Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma 44: 2165–6
Tsimberidou AM, Catovsky D, Schlette E, et al. (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107: 125–35
Nathwani B, Anderson J, Armitage J, et al. (1999) Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 17: 2486–92
Berger F, Felman P, Thieblemont C, et al. (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95: 1950–6
Koh L, Lim L, Thng C (2000) Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 17: 225–8
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Thieblemont, C. (2010). Lymphomes de la zone marginale. In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_15
Download citation
DOI: https://doi.org/10.1007/978-2-287-72070-3_15
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-72069-7
Online ISBN: 978-2-287-72070-3